Cargando…

Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System

OBJECTIVE: This study evaluated the cost-effectiveness of apatinib in patients with chemotherapy-refractory mGC. PATIENTS AND METHODS: A Markov model was developed to simulate the clinical course of typical patients with chemotherapy-refractory metastatic gastric cancer (mGC). We estimated the 10-ye...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Yongrui, Xu, Yuejuan, Wu, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727640/ https://www.ncbi.nlm.nih.gov/pubmed/29317864 http://dx.doi.org/10.1155/2017/2816737

Ejemplares similares

Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward
por: Fornaro, Lorenzo, et al.
Publicado: (2016)

Impact of radiofrequency ablation for patients with varicose veins on the budget of the German statutory health insurance system
por: Kuhlmann, Alexander, et al.
Publicado: (2013)

Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
por: Zhang, Yong, et al.
Publicado: (2017)

A Budget for Medical Care Insurance
por: Falk, I. S.
Publicado: (1947)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma
por: Gao, Shen, et al.
Publicado: (2022)

Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL-17
por: Chen, Ran, et al.
Publicado: (2019)

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
por: Lin, Haimin, et al.
Publicado: (2019)

Budget impact model for oncopharmacogenetics from the perspective of mandatory basic health insurance in Switzerland using the example of breast cancer
por: Szucs, Thomas D, et al.
Publicado: (2018)

Evaluation of Erlotinib in Advanced Non-Small Cell Lung Cancer: Impact on the Budget of a U.S. Health Insurance Plan
por: Ramsey, Scott D., et al.
Publicado: (2006)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
por: Cai, Zhaolun, et al.
Publicado: (2019)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib
por: Yang, Jin-Ru, et al.
Publicado: (2022)

Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
por: Li, Ningning, et al.
Publicado: (2020)

Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study
por: Guo, Yesong, et al.
Publicado: (2019)

Concurrent apatinib and local radiation therapy for advanced gastric cancer: A case report and review of the literature
por: Zhang, Ming, et al.
Publicado: (2017)

A budget impact analysis of substituting sitagliptin with liraglutide in type 2 diabetes from a private health insurance perspective in Egypt
por: Elsisi, Gihan Hamdy, et al.
Publicado: (2022)

Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2018)

Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer
por: Liu, Haipeng, et al.
Publicado: (2022)

Expression of p53 as a biomarker in determining response to apatinib for advanced gastric cancer
por: Qiu, Zhiyuan, et al.
Publicado: (2023)

Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients
por: Huang, Lihong, et al.
Publicado: (2016)

Working with Costs and Budgets
por: Institute of Leadership, et al.
Publicado: (2013)

Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202)
por: Wang, Xiang, et al.
Publicado: (2022)

An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)
por: Wang, Xiang, et al.
Publicado: (2020)

Good budget or good care: The dilemma of social health insurance in Vietnam
por: Vuong, Quan-Hoang, et al.
Publicado: (2021)

Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy
por: Ruan, Hanguang, et al.
Publicado: (2017)

Effectiveness and safety of low‐dose apatinib in advanced gastric cancer: A real‐world study
por: Du, Yingying, et al.
Publicado: (2020)

Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
por: Cui, Qingli, et al.
Publicado: (2022)

Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer
por: Zhang, Yonglei, et al.
Publicado: (2021)

Budget Impact of Introducing Linagliptin into Bosnia and Herzegovina Health Insurance Drug Reimbursement List in 2016-2018
por: Catic, Tarik, et al.
Publicado: (2017)

Application of apatinib after multifaceted therapies for metastatic breast cancer
por: Wang, Jue, et al.
Publicado: (2020)

Apatinib is effective for treatment of advanced hepatocellular carcinoma
por: Kong, Yinlong, et al.
Publicado: (2017)

Apatinib as an alternative therapy for advanced hepatocellular carcinoma
por: Zhang, Xi-Hao, et al.
Publicado: (2020)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study
por: Wang, Chunjing, et al.
Publicado: (2023)

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
por: Kongnakorn, Thitima, et al.
Publicado: (2019)

Apatinib in Combination with S‐1 as First‐Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single‐Arm, Phase II Trial
por: Zhou, Na, et al.
Publicado: (2020)

Cost-effectiveness and budget impact analyses of dengue vaccination in Indonesia
por: Suwantika, Auliya Abdurrohim, et al.
Publicado: (2021)

Cost-Effectiveness and Budget Impact Analyses of Pneumococcal Vaccination in Indonesia
por: Suwantika, Auliya A., et al.
Publicado: (2021)

Cost effectiveness and budget impact of universal varicella vaccination in Russia
por: Marijam, Alen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g47coteepnhf2eoj7m41nivtr1